Outlook Therapeutics (NASDAQ:OTLK) Upgraded at ValuEngine

ValuEngine upgraded shares of Outlook Therapeutics (NASDAQ:OTLK) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, ValuEngine reports.

Several other brokerages also recently issued reports on OTLK. HC Wainwright started coverage on Outlook Therapeutics in a research report on Thursday, July 18th. They issued a buy rating and a $8.00 price target on the stock. CIBC started coverage on Outlook Therapeutics in a research report on Thursday, May 16th. They issued an outperform rating and a $12.00 price target on the stock. Ascendiant Capital Markets started coverage on Outlook Therapeutics in a research report on Monday, April 22nd. They issued a buy rating and a $4.00 price target on the stock. Finally, Oppenheimer started coverage on Outlook Therapeutics in a research report on Thursday, May 16th. They issued an outperform rating and a $12.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and an average target price of $9.00.

Shares of NASDAQ:OTLK traded up $0.02 during midday trading on Thursday, hitting $2.16. The company’s stock had a trading volume of 132,259 shares, compared to its average volume of 1,790,031. The firm has a market capitalization of $60.70 million, a PE ratio of -0.20 and a beta of -0.86. The stock’s 50 day moving average is $2.20. Outlook Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $10.96.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.08. The business had revenue of $0.64 million during the quarter. As a group, research analysts forecast that Outlook Therapeutics will post -2 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Outlook Therapeutics stock. Chicago Capital LLC purchased a new stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,450 shares of the company’s stock, valued at approximately $40,000. Chicago Capital LLC owned about 0.07% of Outlook Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.87% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Further Reading: Straddles

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.